Brief: Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
BRIEF-Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia Oct 15 (Reuters) - Modus Therapeutics Holding AB (publ) MODTX.ST:
SAID ON WEDNESDAY VOLUNTARILY DECIDED, AS A PRECAUTIONARY MEASURE, TO TEMPORARILY PAUSE ENROLLMENT IN PART 2 OF THE ONGOING PHASE IIA STUDY OF SEVUPARIN WITHIN THE CO'S PROGRAM IN CKD WITH ANEMIA
THE DECISION WAS MADE AFTER A SERIOUS ADVERSE EVENT IN A PATIENT TREATED WITH SEVUPARIN WAS REPORTED
THE PAUSE IS NOT THE RESULT OF A REGULATORY DECISION
PRELIMINARY ASSESSMENT IS THAT THE PAUSE WILL SHIFT THE PROOF-OF-CONCEPT READOUT FROM AROUND THE TURN OF THE YEAR 2026/2027 TO Q1 2027
ANY EFFECTS OF PAUSE ON COSTS, TIMELINE TO BE REFLECTED IN UPDATED ASSESSMENT OF CO'S FINANCING THAT MODUS INTENDS TO PRESENT IN Q3 INTERIM REPORT ON NOVEMBER 24, 2026
Source text: nMFN4m1bRD
Further company coverage: MODTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Modus Therapeutics Holding AB
See all newsBrief: Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
Brief: Modus Gets SEK 0.13 Mln Through Exercise Of Warrants
Brief: Modus Therapeutics Resolves On Directed Share Issue Of 20 Million Shares
Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Brief: Modus Therapeutics Q2 Net Income SEK -4.645 Million